Skip to main content

Table 2 Immunoexpression of luminal and basal markers in the bladder cancer cohort

From: Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression

 

GATA3 and FOXA1 −

GATA3 and/or FOXA1 +

 WHOLE COHORT

  CK5/6 −

4 (3.1%)

66 (52.4%)

  CK5/6 +

5 (4.0%)

51 (40.5%)

 NMIBC

  CK5/6 −

1 (2.0%)

30 (58.8%)

  CK5/6 +

1 (2.0%)

19 (37.2%)

 MIBC

  CK5/6 −

3 (4.2%)

35 (48.6%)

  CK5/6 +

4 (5.5%)

30 (41.7%)

  1. MIBC muscle invasive bladder cancer, NMIBC non-muscle invasive bladder cancer
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us